Navigation Links
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
Date:4/29/2009

- Primary Endpoint met With a Significant Reduction in Relapse Rate

- Secondary Endpoints met Including MRI Measures, Proportion of Patients Relapse-Free and Disability Progression

- Submission for Registration of Cladribine Tablets Planned for mid-2009

SEATTLE and GENEVA, April 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, announced today detailed results of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using Cladribine Tablets (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The results of the pivotal trial show that annual short-course treatment with Cladribine Tablets led to a significant reduction in the rate of clinical relapses, disability progression and brain lesions, as well as a significant increase in the proportion of patients who remained relapse-free. The data were presented today for the first time, as a late-breaking oral presentation at the 61st Annual Meeting of the American Academy of Neurology (AAN) in Seattle, WA.

"All primary and secondary endpoints of the CLARITY study were statistically significant and demonstrate that annual short-course treatment with Cladribine Tablets in this study was effective across multiple important clinical and MRI efficacy measures," said Dr. Gavin Giovannoni, principal investigator of the study, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, United Kingdom.

"We are very pleased with the successful outcome of the CLARITY study," said Elmar Schnee, President of Merck Serono. "This is an exciting development in multiple sclerosis clinical research, and represents an important step towards delivering an oral therapy to people living with this condition."

The results from both Cladribine Tablets treatment groups in the study d
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
11. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that 2015 first quarter ... 2015.  On that day, the Company will hold a ... Time to discuss the results, followed by a question ... Chairman, President and Chief Executive Officer of CryoLife, Inc. ...
(Date:4/21/2015)... Mary Kelly, Ph.D ., is helping members of the Medical Group Managers Associations (MGMA) deal ... http://photos.prnewswire.com/prnh/20150420/199849 ... ... ... pulling your hair out of your head or going bankrupt," said Kelly, a popular keynote ...
(Date:4/21/2015)...  Edico Genome today announced a collaboration with ... processors to accelerate next generation sequencing (NGS) data ... primary and secondary NGS analysis in real time, ... analysis in the cloud and holds benefits for ... such as analysis of population-scale genomic data. ...
Breaking Medicine Technology:CryoLife Announces Release Date and Teleconference Call Details for 2015 First Quarter Financial Results 2Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 2Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 3Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 4Medical Group Managers Build Effective Practices with Strategies from Leadership Expert Mary Kelly 5Edico Genome Collaborates with Intel to Overcome Big Data Bottleneck in Next-Generation Sequencing 2Edico Genome Collaborates with Intel to Overcome Big Data Bottleneck in Next-Generation Sequencing 3
... Inc.,("CeloNova"), leading and accelerating healthcare solutions through ... breakthrough,results from the ATLANTA study of the ... the 20th Annual International Symposium on,Endovascular Therapy ... Corrado Tamburino, MD, President of the ...
... Ortho Women,s Health,& Urology(TM), Division of ... for ORTHO EVRA(R),(norelgestromin/ethinyl estradiol transdermal system) to ... includes two new additional estimates of relative,risk ... of 1.1,(indicating no increase in risk) and ...
Cached Medicine Technology:CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F 2ORTHO EVRA(R) Prescribing Information Updated 2ORTHO EVRA(R) Prescribing Information Updated 3
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
(Date:4/21/2015)... TX (PRWEB) April 21, 2015 The ... announced today it is opening its first freestanding emergency ... in Chandler, Arizona and will be licensed under Dignity ... the Dignity Health and Adeptus Health joint venture. , ... Regional and Mercy Gilbert Medical Centers said the new ...
(Date:4/21/2015)... & New York, NY (PRWEB) April 21, 2015 ... global provider of advanced delivery technologies and development ... today announced the launch of ADVASEPT™ Lock, a ... and efficient delivery of injectable medications. Easily opened, ... a safe, convenient and functional container closure with ...
(Date:4/21/2015)... Carinsurancehints.com has released a new blog post presenting ... auto insurance prices . , Commuting on ... should review their insurance options before deciding what plan ... forms. Some of the popular policies provide liability, collision ... rates and find the best prices in their area ...
(Date:4/21/2015)... April 21, 2015 This year, in ... Skin Types, Inc.® (FIRST) will publish a unique awareness ... will run throughout the month of May and carry ... to Someone." The positioning was chosen to encourage ... skin disorder and to help support our mission of ...
Breaking Medicine News(10 mins):Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
... /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) Inc. (NYSE: ... device research and development outsourcing company with ... announced it has reached an agreement,with Johnson ... of,Janssen Pharmaceutica, N.V. (J&JPRD) to expand its ...
... ST. LOUIS, Oct. 15 Young Innovations, Inc.,(Nasdaq: ... third quarter,earnings results with a live and on-demand web ... Central Time. A live audio broadcast of the,call will ... the live audio broadcast will also be available through ...
... Options,(CCO), a leader in the development of innovative online, ... agreement with,the American Association for the Study of Liver ... unique Conference Coverage of AASLD,s,Liver Meeting(R) 2008, which will ... 4, 2008., "Clinical Care Options has a proven ...
... DUBLIN, Ohio, Oct. 15 Foresight Corporation ... Debra Strickland has joined the,company,s Development division ... http://www.newscom.com/cgi-bin/prnh/20081015/CLW134 ), In this role, ... customers to,propose and design new technical solutions, ...
... 15 Darwin,Professional Underwriters, Inc. (the "Company") (NYSE: ... meeting of the Company,s stockholders held on October ... Plan of Merger,(the "Merger Agreement"), dated as of ... Company Holdings, Ltd ("Allied World") and Allied,World Merger ...
... a sentry guarding the castle walls, a molecular messenger inside ... that could allow the invasion of an insidious enemy: Cancer. ... in its tracks, preventing an error that could lead to ... suggests that to be able to prevent abnormal cell proliferation, ...
Cached Medicine News:Health News:WuXi PharmaTech Expands Collaboration for Fully Integrated Services 2Health News:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2Health News:American Association for the Study of Liver Diseases Enters Into Agreement With Clinical Care Options as Its Authorized Online Conference Coverage Provider for the Liver Meeting(R) 2008 2Health News:Debra Strickland joins Foresight Corporation in time for HIPAA 5010 Mandate 2Health News:Darwin Stockholders Adopt Merger Agreement with Allied World 2Health News:Darwin Stockholders Adopt Merger Agreement with Allied World 3Health News:Stem-cell sentry sounds the alarm to maintain balance between cancer and aging, U-M researchers find 2
... Microplate washer MP-1200 is a compact ... system. Its internal micropumps enable the ... discharge from all types of microtiter ... be washed in rows of 8 ...
Wellwash 384 is an efficient, rapid and reliable washing process for high-throughput screening. It has been designed to optimize the washing process and ensure the best results. Available in 384 or 9...
... Designed and manufactured specifically ... MultiWash II delivers the ... demand. The MultiWash II ... dependable accuracy, while providing ...
... PDQ Plus for the determination of A1c is ... The PDQ Plus is a fully automated analyzer ... for the ultimate in safety and positive identification. ... well known to be interference-free and to produce ...
Medicine Products: